Browsing Tag
Shanghai
31 posts
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Is Cathay General Bancorp (Nasdaq: CATY) a quiet bank stock to watch before earnings?
Cathay General Bancorp (Nasdaq: CATY) heads into April 22 earnings near its 52-week high. Read what matters next for this regional bank stock.
Haleon (NYSE, LSE: HLN) bets on China’s oral health boom with £65m Shanghai manufacturing facility
Haleon invests £65M in a Shanghai oral health plant to expand Sensodyne and parodontax across China. Discover what this move signals for the global oral care market.
MySize Inc. (NASDAQ: MYSZ) sharpens Asia-Pacific strategy as fashion retailers turn to AI for inventory precision
Find out why MySize Inc. is betting big on Asia-Pacific as it brings its AI-powered fashion platform to Shanghai’s LINK FASHION 2026.
From Seoul to Shanghai: How Lubrizol’s new foam centers aim to reshape the global footwear midsole market
Lubrizol opens Foam Centers of Excellence in Seoul and Shanghai to pioneer sustainable TPU foams. Discover how this move reshapes footwear midsoles.
FDA clears Mabwell’s next-gen ADC 7MW4911: What’s at stake in the global GI oncology race?
Mabwell secures FDA IND for CDH17-targeting ADC 7MW4911, marking a major step in GI cancer therapy. Find out how this could reshape advanced oncology care.
Markel Group (NYSE: MKL) finalizes MECO Group acquisition to expand global marine insurance portfolio
Markel Group completes MECO acquisition to boost marine specialty insurance operations across key global markets. Explore the strategic impact.
CirCode Biomed’s HM2002 gets FDA green light: World’s first circular RNA drug to enter U.S. clinical trials for heart disease
CirCode’s HM2002 becomes the first circular RNA drug cleared by the FDA for clinical trials in ischemic heart disease—setting a precedent in RNA therapeutics.
CARsgen’s CT0596 CAR-T shows strong early results in refractory myeloma
CARsgen’s allogeneic CAR-T therapy CT0596 shows early safety and efficacy in myeloma—find out how investors are reacting to the 2025 breakthrough.
Why did China’s stock market crash and how did its sovereign wealth fund respond?
Find out how China’s sovereign wealth fund is stepping in to stabilise markets amid a deepening trade war and rising global recession fears.